Dr. Gahl and his team at the National Human Genome Research Institute are seeking volunteers aged 18 and older with primary FSGS to participate in a research study on the effects of an experimental drug, ManNAc, on this disease. The study aims to assess the long-term safety and tolerability of ManNAc and determine whether it can reduce protein in the urine of people with FSGS.
The study includes a physical examination, a review of medical and family history, urine tests, and blood draws. Participants will need to make two inpatient visits to the NIH (each lasting 2-3 overnights) and three to four outpatient NIH visits (lasting a few hours each). ManNAc, an experimental sugar-based drug, is taken orally as a powder dissolved in water twice daily.
Travel and lodging will be covered. Compensation up to $2,000 over the course of the study will be provided.
For More Information
NIH Clinical Center Office of Patient Recruitment
833-JOIN-NIH
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online
Refer to NIH study # 002066-HG
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Human Genome Research Institute (NHGRI)